Biotech firm Tychan to start human trials for Covid-19 treatment next week
The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody, or immune system protein that specifically targets the virus that causes Covid-19
Singapore: A Singaporean biotechnology firm, Tychan, will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19, it said in a statement on Wednesday.The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody, or immune system protein that specifically targets the...
Singapore: A Singaporean biotechnology firm, Tychan, will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19, it said in a statement on Wednesday.
The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody, or immune system protein that specifically targets the virus that causes Covid-19.
Antibodies are generated in the body to fight off infection. Monoclonal antibodies mimic natural antibodies and can be isolated and manufactured in large quantities to treat diseases in patients.
Read also: Panacea Biotec, Refana enter landmark collaboration for COVID-19 Vaccine
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd